Brief: Vivoryon Therapeutics Net Loss Narrows At EUR 5.1 Million

Vivoryon Therapeutics NV

16/05/2023 07:50

May 16 (Reuters) - Vivoryon Therapeutics NV  05Y.F :
    * VIVORYON THERAPEUTICS N.V. REPORTS Q1 2023 FINANCIAL
RESULTS AND
HIGHLIGHTS OPERATIONAL PROGRESS
    * NO REVENUES WERE GENERATED IN Q1 OF 2023
    * NET LOSS FOR THREE MONTHS ENDED MARCH 31, 2023, WAS EUR
5.1
MILLION, COMPARED TO EUR 6.4 MILLION FOR THREE MONTHS ENDED
MARCH 31, 2022
    * RESEARCH AND DEVELOPMENT EXPENSES DECREASED BY EUR 2.7
MILLION
TO EUR 3.1 MILLION IN THREE MONTHS ENDED MARCH 31, 2023,
COMPARED TO EUR 5.8 MILLION IN THREE MONTHS ENDED MARCH 31, 2022
    * HELD EUR 17.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF
MARCH
31, 2023, COMPARED TO EUR 26.6 MILLION AS OF DECEMBER 31, 2022
    * VIVORYON EXPECTS THAT ITS EXISTING CASH AND CASH
EQUIVALENTS
WILL BE SUFFICIENT TO FUND ITS RESEARCH AND DEVELOPMENT EXPENSES
AS WELL GENERAL AND ADMINISTRATIVE EXPENSES AND CASH FLOWS FROM
INVESTING AND FINANCING ACTIVITIES AT LEAST THROUGH END OF
DECEMBER 2023

Source text for Eikon:  ID:nGNE31rdSK 
Further company coverage:  05Y.F 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))